BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ameratunga M, Chénard-poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J. Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. European Journal of Cancer 2018;89:56-63. [DOI: 10.1016/j.ejca.2017.11.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Fang Q, Yu J, Li W, Luo J, Deng Q, Chen B, He Y, Zhang J, Zhou C. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy. Clin Exp Pharmacol Physiol 2023;50:178-90. [PMID: 36419356 DOI: 10.1111/1440-1681.13740] [Reference Citation Analysis]
2 Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:579-97. [PMID: 36636451 DOI: 10.1016/j.jaccao.2022.09.004] [Reference Citation Analysis]
3 Sui Q, Zhang X, Chen C, Tang J, Yu J, Li W, Han K, Jiang W, Liao L, Kong L, Li Y, Hou Z, Zhou C, Zhang C, Zhang L, Xiao B, Mei W, Xu Y, Qin J, Zheng J, Pan Z, Ding PR. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nat Commun 2022;13:7316. [PMID: 36443332 DOI: 10.1038/s41467-022-35096-6] [Reference Citation Analysis]
4 Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, Han X. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics 2022;12:6273-90. [PMID: 36168626 DOI: 10.7150/thno.76854] [Reference Citation Analysis]
5 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
6 Hwang M, Canzoniero JV, Rosner S, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T, Anagnostou V. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer 2022;10:e004688. [PMID: 35688557 DOI: 10.1136/jitc-2022-004688] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Huang J, Guo Y, Huang W, Hong X, Quan Y, Lin L, Zhou J, Liang L, Zhang Y, Zhou J, Cai M, Zhu K. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. JHC 2022;Volume 9:157-70. [DOI: 10.2147/jhc.s353956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
9 Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [DOI: 10.4251/wjgo.v14.i1.19] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gou M, Qu T, Wang Z, Yan H, Si Y, Zhang Y, Dai G. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer. J Immunol Res 2021;2021:2549295. [PMID: 34993252 DOI: 10.1155/2021/2549295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Hsiang CW, Huang WY, Yang JF, Shen PC, Dai YH, Wang YF, Lin CS, Chang WC, Lo CH. Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1299-309. [PMID: 34765571 DOI: 10.2147/JHC.S334933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Yang K, Han L, Wu S, Qu X, Li Q, Zhao C, Zhou J, Jin X, Wang Y, Yan D, Cheng Z, Hua Y, Zhang Y, Ge Y, Sun J, Deng W, Zhao L, Zhao Y. Real-world outcomes of regorafenib combined with immune checkpoint inhibitors in patients with advanced or metastatic microsatellite stable colorectal cancer: A multicenter study. Cancer Immunol Immunother 2021. [PMID: 34689233 DOI: 10.1007/s00262-021-03083-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li X, Shi H, Zhang W, Bai C, He M, Ta N, Huang H, Ning Y, Fang C, Qin H, Dong Y. Immunotherapy and Targeting the Tumor Microenvironment: Current Place and New Insights in Primary Pulmonary NUT Carcinoma. Front Oncol 2021;11:690115. [PMID: 34660264 DOI: 10.3389/fonc.2021.690115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Pu D, Xu Q, Zhou LY, Zhou YW, Liu JY, Ma XL. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors. Thorac Cancer 2021;12:2914-23. [PMID: 34581010 DOI: 10.1111/1759-7714.14152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
15 Lecot P, Ardin M, Dussurgey S, Alcazer V, Moudombi L, Hubert M, Swalduz A, Hernandez-vargas H, Viari A, Caux C, Michallet M. Gene signature of circulating platelet-bound neutrophils is associated with poor prognosis in cancer patients.. [DOI: 10.1101/2021.08.26.457803] [Reference Citation Analysis]
16 Mortezaee K. Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives. Life Sci 2021;277:119627. [PMID: 34004256 DOI: 10.1016/j.lfs.2021.119627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
17 Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer 2021;9:e002478. [PMID: 33879601 DOI: 10.1136/jitc-2021-002478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
18 Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 2021;12:729. [PMID: 33526794 DOI: 10.1038/s41467-021-20935-9] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 39.0] [Reference Citation Analysis]
19 Fountzilas C, Evans R, Alaklabi S, Iyer R. Immunotherapy in hepatocellular cancer. Adv Cancer Res 2021;149:295-320. [PMID: 33579426 DOI: 10.1016/bs.acr.2020.12.002] [Reference Citation Analysis]
20 Nakamura K, Okuyama R, Kawakami Y. Renin-Angiotensin System in the Tumor Microenvironment. Adv Exp Med Biol 2020;1277:105-14. [PMID: 33119868 DOI: 10.1007/978-3-030-50224-9_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Gavrilov S, Zhudenkov K, Helmlinger G, Dunyak J, Peskov K, Aksenov S. Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab. CPT Pharmacometrics Syst Pharmacol 2021;10:67-74. [PMID: 33319498 DOI: 10.1002/psp4.12578] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Viñal D, Gutierrez-sainz L, Martinez D, Garcia-cuesta JA, Pedregosa J, Villamayor J, Ostios L, Sanchez-cabrero D, Higuera O, Pinto A, Rodriguez-salas N, Espinosa E, de Castro J, Feliu J. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clin Transl Oncol 2021;23:1185-92. [DOI: 10.1007/s12094-020-02509-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Park JC, Durbeck J, Clark JR. Predictive value of peripheral lymphocyte counts for immune checkpoint inhibitor efficacy in advanced head and neck squamous cell carcinoma. Mol Clin Oncol 2020;13:87. [PMID: 33194194 DOI: 10.3892/mco.2020.2157] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
24 Li S, Zhang C, Pang G, Wang P. Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Front Immunol 2020;11:603157. [PMID: 33178229 DOI: 10.3389/fimmu.2020.603157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
25 Wiesweg M, Mairinger F, Reis H, Goetz M, Kollmeier J, Misch D, Stephan-Falkenau S, Mairinger T, Walter RFH, Hager T, Metzenmacher M, Eberhardt WEE, Zaun G, Köster J, Stuschke M, Aigner C, Darwiche K, Schmid KW, Rahmann S, Schuler M. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context. Eur J Cancer 2020;140:76-85. [PMID: 33059196 DOI: 10.1016/j.ejca.2020.09.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
26 Xiong Q, Huang Z, Xin L, Qin B, Zhao X, Zhang J, Shi W, Yang B, Zhang G, Hu Y. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. Cancer Immunol Immunother 2021;70:713-20. [PMID: 32910245 DOI: 10.1007/s00262-020-02706-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
27 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Fan J, Shen X, Wang Y, Zhou HL, Liu G, Li YL, Xu ZX. Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomed Pharmacother 2020;130:110621. [PMID: 34321165 DOI: 10.1016/j.biopha.2020.110621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Janus GA, Ievleva AG, Suspitsyn EN, Tyurin VI, Bizin IV, Gorustovich OA, Ni VI, Kholmatov MM, Laidus TA, Chuynyshena SA, Aleksakhina SN, Imyanitov EN. PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS. Sib onkol ž 2020;19:123-131. [DOI: 10.21294/1814-4861-2020-19-4-123-131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Mroweh M, Decaens T, Marche PN, Macek Jilkova Z, Clément F. Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5250. [PMID: 32722054 DOI: 10.3390/ijms21155250] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
31 Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, Thouvenin J, Barthelemy P, Thibault C, Tartour E, Oudard S, Vano YA. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother 2020;69:2513-22. [PMID: 32561968 DOI: 10.1007/s00262-020-02637-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
32 Tatsumi A, Maekawa Y, Komori Y, Yamamoto K, Hamaguchi T, Takahashi K, Kunimasa J. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive Factors for Serious Nivolumab-Induced Immune-Related Adverse Events. Jpn J Pharm Health Care Sci 2020;46:331-339. [DOI: 10.5649/jjphcs.46.331] [Reference Citation Analysis]
33 Yamada T, Hayashi T, Inokuchi Y, Hayashi K, Watanabe H, Komori K, Kano K, Shimoda Y, Fujikawa H, Shiozawa M, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy. Targ Oncol 2020;15:317-25. [DOI: 10.1007/s11523-020-00716-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Nunno VD, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, Massari F. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. 2019;11:631-643. [PMID: 30943858 DOI: 10.2217/imt-2018-0175] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
35 Kim KH, Sim NS, Chang JS, Kim YB. Tumor immune microenvironment in cancer patients with leukocytosis. Cancer Immunol Immunother 2020;69:1265-77. [PMID: 32170377 DOI: 10.1007/s00262-020-02545-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Jiang Y, Zhao X, Fu J, Wang H. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. Front Immunol 2020;11:339. [PMID: 32226426 DOI: 10.3389/fimmu.2020.00339] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 14.3] [Reference Citation Analysis]
37 Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, Berruti A, Falcone A, Aieta M, Gelibter A, Russo A, Barni S, Maio M, Martelli O, Pantano F, Iacono D, Calvetti L, Quadrini S, Roca E, Vasile E, Imperatori M, Occhipinti M, Galvano A, Petrelli F, Calabrò L, Pasquini G, Intagliata S, Ricciardi GRR, Tonini G, Santini D, Adamo V. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. Adv Ther 2020;37:1145-55. [PMID: 32002809 DOI: 10.1007/s12325-020-01229-w] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 18.7] [Reference Citation Analysis]
38 Orfanu A, Aramă V, Popescu C, Tilişcan C, Streinu-Cercel A, Aramă ŞS. The Dynamical Assessment of Inflammatory Biomarkers in Predicting the Outcome of Septic Patients and the Response to Antimicrobial Therapy. J Crit Care Med (Targu Mures) 2020;6:25-31. [PMID: 32104728 DOI: 10.2478/jccm-2020-0004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Ker C, Tong H, Yang M, Tseng I, Chang D, Chen H, Wang B, Ko C, Chao C, Chen Y. Role of Pre-Operative of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in Prognosis of Hepatocellular Carcinoma. IJCM 2020;11:491-503. [DOI: 10.4236/ijcm.2020.119042] [Reference Citation Analysis]
40 Lecot P, Sarabi M, Pereira Abrantes M, Mussard J, Koenderman L, Caux C, Bendriss-Vermare N, Michallet MC. Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Front Immunol 2019;10:2155. [PMID: 31616408 DOI: 10.3389/fimmu.2019.02155] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 20.5] [Reference Citation Analysis]
41 Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer. Int J Clin Oncol 2020;25:74-81. [PMID: 31531785 DOI: 10.1007/s10147-019-01539-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
42 Juliá EP, Mandó P, Rizzo MM, Cueto GR, Tsou F, Luca R, Pupareli C, Bravo AI, Astorino W, Mordoh J, Martín C, Levy EM. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunol Immunother 2019;68:1585-96. [DOI: 10.1007/s00262-019-02391-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
43 Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:396. [PMID: 31500650 DOI: 10.1186/s13046-019-1396-4] [Cited by in Crossref: 159] [Cited by in F6Publishing: 169] [Article Influence: 39.8] [Reference Citation Analysis]
44 Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol 2019;145:2541-6. [PMID: 31367835 DOI: 10.1007/s00432-019-02982-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
45 Weed DT, Zilio S, Reis IM, Sargi Z, Abouyared M, Gomez-Fernandez CR, Civantos FJ, Rodriguez CP, Serafini P. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial. Front Immunol 2019;10:1206. [PMID: 31214178 DOI: 10.3389/fimmu.2019.01206] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
46 Li Y, Liu J, Gao L, Liu Y, Meng F, Li X, Qin FX. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. Immunol Lett 2020;220:88-96. [PMID: 30885690 DOI: 10.1016/j.imlet.2019.03.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
47 Hazama S. Revolution in Cancer Immunotherapy and its Perspective. Yamaguchi Medical Journal 2019;68:5-12. [DOI: 10.2342/ymj.68.5] [Reference Citation Analysis]
48 Soda H, Ogawara D, Fukuda Y, Tomono H, Okuno D, Koga S, Taniguchi H, Yoshida M, Harada T, Umemura A, Yamaguchi H, Mukae H. Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study. Thorac Cancer 2019;10:341-6. [PMID: 30582295 DOI: 10.1111/1759-7714.12952] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
49 Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, Mori M, Satoh T, Doki Y, Wada H. Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother 2018;67:1673-83. [PMID: 30128737 DOI: 10.1007/s00262-018-2225-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
50 Namikawa T, Ishida N, Tsuda S, Fujisawa K, Munekage E, Iwabu J, Munekage M, Uemura S, Tsujii S, Maeda H, Kitagawa H, Kobayashi M, Hanazaki K. Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab. Surg Case Rep 2018;4:71. [PMID: 29978335 DOI: 10.1186/s40792-018-0479-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
51 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]